Akums Drugs and Pharmaceuticals Limited — PPTs, 26-05-2025: Investor Presentation

1. Financial Highlights:

Akums reported flat consolidated revenue of ₹4,170 Cr for FY25 (-1%), with adjusted EBITDA margin expanding to 12.3% (+7bps) and adjusted PAT margin rising to 5.6% (+38bps). Q4 revenue rose 12.4% to ₹1,073 Cr while PAT margin slightly dipped to 4.1%. The CDMO segment saw stable EBITDA margin (~14%), although revenue declined slightly due to weaker API prices and moderate volume growth. Domestic and international branded formulations grew by 8.9% and 14.3% respectively, while trade generics revenue dropped sharply (-34.9%) following strategic consolidation. Net debt stands at ₹566 Cr with strong operating cash flow coverage (~91%). R&D expenditure increased 16% YoY to ₹130 Cr.

2. Strategic Initiatives & Growth Drivers:

Akums is advancing its global CDMO ambitions through a EUR 200 Mn contract for deliveries starting 2027, backed by facility expansions including a new injectable plant focusing on sterile drugs. The company continues significant R&D investment (~3.8% of revenue) with 31 new DCGI approvals, alongside capacity increases in complex dosage forms and nasal sterile technologies. Emphasis remains on branded formulations growth and export market expansion.

3. Business Developments:

Operationalization of the new injectable facility and Baddi expansion mark key developments. Completed ₹1,280 Cr capex over five years, with acquisition opportunities being explored to drive inorganic growth. The supplier base has been broadened domestically to reduce global supply risks, supporting a client base of 1,400+ customers and 1,800 suppliers.

4. Market Position & Competitive Advantage:

Akums dominates the Indian pharma CDMO sector with roughly 3x the revenue and 2x the capacity of its next largest competitor. It benefits from deep client relationships averaging 15+ years, extensive regulatory compliance (350+ audits), a large niche product portfolio, and a wide dosage form range across 11 manufacturing sites. A robust field force and specialized formulations expertise reinforce its market standing.

5. Investor Implications:

Steady margins, rising R&D, and secured global CDMO contracts point to positive growth potential despite pricing pressures and volume softness in APIs. Key risks include API business turnaround and scaling the injectable unit. The diversified business model and solid balance sheet underpin sustainable value creation. Investors should monitor contract execution and growth in niche, higher-margin products.